Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Conditions
- Allogeneic Stem Cell Transplant Recipient
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- DRUG: Cytarabine Hydrochloride
- DRUG: Fludarabine
- BIOLOGICAL: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Sponsor
Sumithira Vasu
Collaborators